Abstracts tagged "COVID-19"

Abstract Number: 1539 • ACR Convergence 2021
High Disease Activity, as Assessed by RAPID3, Increases Risk of Hospitalization and Predicts Lower Chance of Recovery from COVID-19 in a Cohort of Tertiary Care Rheumatology Patients
Matas Orentas¹, Sonali Khandelwal², Michael Grant², Yanyu Zhang¹, Najia Shakoor² and Sobia Hassan¹, ¹RUMC, Chicago, IL, ²Rush University, Chicago, IL
Background/Purpose: There is a need to understand which patients with rheumatologic diseases may be at highest risk for poor COVID-19 related outcomes so that both…
Abstract Number: 1557 • ACR Convergence 2021
Immunogenicity and Safety of an Inactivated Virus Vaccine Against SARS-CoV-2 in Patients with Autoimmune Rheumatic Diseases
Ana Medeiros-Ribeiro¹, Nadia Aikawa¹, Carla Gonçalves Schahin Saad¹, Emily Figueiredo Vieira Neves Yuki¹, Tatiana do Nascimento Pedrosa¹, Solange Fusco¹, Priscila Rojo¹, Rosa Pereira¹, Samuel Shinjo¹, Danieli Andrade¹, Percival Sampaio-Barros¹, Carolina Ribeiro¹, Giordano Deveza¹, Victor Adriano de Oliveira Martins¹, Clovis Artur Silva¹, Marta Lopes¹, Alberto Duarte¹, Leila Antonangelo¹, Ester Sabino¹, Esper Kallas¹, Sandra Gofinet Pasoto² and Eloisa Bonfá¹, ¹Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Hospital das Clinicas de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Brazil is among the countries with the highest numbers of confirmed cases and deaths by COVID-19. CoronaVac (SARS-CoV-2 inactivated vaccine) has been largely used…
Abstract Number: 1599 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on the Quality of Life of Patients with Rheumatic Conditions: A Qualitative Analysis of Perceived Risk and Decision Making
Courtney Wells¹, Guadalupe Torres², William Nowell³, Shilpa Venkatachalam³, Laura Stradford⁴, Kelly Gavigan³, Barbara Boyd-Floering⁵, Maria I. Danila⁶ and Kristine Carandang⁷, ¹University of Wisconsin-River Falls, White Bear Lake, MN, ²Patient Partner, Brooklyn Center, MN, ³Global Healthy Living Foundation, Upper Nyack, NY, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Whelton Virshup CreakyJoints Arthritis Clinic/ Global Healthy Living Foundation, Lake Worth, FL, ⁶University of Alabama at Birmingham, Birmingham, AL, ⁷Independent, San Diego, CA
Background/Purpose: The purpose of this qualitative study was to understand the concerns, behaviors, and experiences of adults with autoimmune rheumatic conditions, and to evaluate the…
Abstract Number: 1623 • ACR Convergence 2021
Impact of the COVID-19 Pandemic on Presentation of JIA to Pediatric Rheumatology Care in Canada
Molly Dushnicky¹, Catherine Campbell¹, Karen Beattie¹, Roberta Berard², Tania Cellucci³, Mercedes Chan⁴, Tommy Gerschman⁵, Kristin Houghton⁵, Nicole Johnson⁶, Claire LeBlanc⁷, Lillian Lim⁸, Nadia Luca⁹, Paivi Miettunen⁶, Kimberly Morishita⁵, Jean-Philippe Proulx-Gauthier¹⁰, Dax Rumsey¹¹, Heinrike Schmeling⁶, Rosie Scuccimarri¹², Herman Tam¹³, Jaime Guzman¹⁴ and Michelle Batthish¹, ¹McMaster University, Hamilton, ON, Canada, ²London Health Sciences Centre, London, ON, Canada, ³McMaster Children's Hospital, Hamilton, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵University of British Columbia, Vancouver, BC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷Montreal Children's Hospital/McGill University Health Centre, Montréal, QC, Canada, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹Alberta Children's Hospital, Calgary, AB, Canada, ¹⁰CHU de Quebec - Universite Laval, Québec City, QC, Canada, ¹¹University of Alberta, Edmonton, AB, Canada, ¹²McGill University/Montreal Children's Hospital, Montréal, QC, Canada, ¹³Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ¹⁴University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The COVID-19 pandemic has disrupted the delivery of routine healthcare and clinical research around the world. Several reports have shown an impact on rheumatology…
Abstract Number: L01 • ACR Convergence 2020
Outcomes of COVID-19 Infection in Patients with Rheumatic Diseases in a Multicenter Healthcare System: A Comparative Cohort Study
Naomi Serling-Boyd¹, Kristin D'Silva¹, Tiffany Hsu², Xiaoqing Fu³, Rachel Wallwork⁴, April Jorge¹, Yuqing Zhang¹, Ellen Gravallese⁵, Hyon K. Choi⁶, Jeffrey Sparks⁷ and Zachary Wallace⁸, ¹Massachusetts General Hospital, Boston, MA, ²Brigham and Women's Hospital, Jamaica Plain, MA, ³Mass General Hospital, Boston, MA, ⁴Johns Hopkins Hospital, Baltimore, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Massachusetts General Hospital, Newton, MA
Background/Purpose: The risk of poor outcomes from COVID-19 among rheumatic disease patients compared to the general population remains poorly understood. Filling this knowledge gap is…
Abstract Number: L02 • ACR Convergence 2020
Risk Mitigating Behavior in People with Rheumatic Diseases or Psoriasis During the COVID-19 Pandemic Differ by Immunosuppressant Treatment Type: A Patient survey Study
Mark Yates¹, Satveer Mahil¹, Sinead Langan², Claudia De la cruz³, Paola diMeglio¹, Nick Dand¹, Zenas Yiu⁴, Kayleigh Mason⁴, Teresa Tsakok¹, Freya Meynall⁵, Helen McAteer⁶, John Weinman¹, Paolo Gisondi⁷, Luis Puig Sanz⁸, Richard Warren⁴, Francesca Capon¹, Jullien Denis⁹, Tiago Torres¹⁰, Chris Griffiths⁴, Jonathan Barker¹, Kimme Hyrich⁴, Andrew Cope¹, Ian Bruce⁴, Iain McInnes¹¹, Raj Sengupta¹², Helena Marzo-Ortega¹³, Matthew Brown¹, James Galloway¹ and Catherine Smith¹, ¹King's College London, London, United Kingdom, ²London School of Hygiene and Tropical Medicine, London, United Kingdom, ³University of Santiago, Santiago, Chile, ⁴University of Manchester, Manchester, United Kingdom, ⁵Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁶Psoriasis Association, London, United Kingdom, ⁷University of Verona, Verona, Italy, ⁸Hospital de la Santa Creu I Sant Pau, Barcelona, Spain, ⁹Hospices Civils de Lyon, Lyon, France, ¹⁰University of Porto, Porto, Portugal, ¹¹University of Glasgow, Glasgow, United Kingdom, ¹²Royal United Hospitals Bath, Bath, United Kingdom, ¹³University of Leeds, Leeds, United Kingdom
Background/Purpose: Clinician-reported registry data suggest that use of biologics in people with immune-mediated inflammatory diseases (IMIDs) is associated with a lower risk of adverse COVID-19…
Abstract Number: L05 • ACR Convergence 2020
DMARD Changes for Patients with Rheumatoid Arthritis in the US During the First Three Months of the COVID-19 Pandemic
Kaleb Michaud¹, Sofia Pedro², Kristin Wipfler³, Ekta Agarwal⁴ and Patricia Katz⁵, ¹University of Nebraska Medical Center and Forward, the National Databank for Rheumatic Diseases, Omaha, NE, ²Forward, The National Databank for Rheumatic Diseases, Wichita, KS, ³FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, ⁴Pfizer inc, Princeton Jct, NJ, ⁵UCSF, Mill Valley, CA
Background/Purpose: To understand medication and clinical care changes by patients with RA during the first 3 months (March through May 2020) of the COVID-19 pandemic…
Abstract Number: L07 • ACR Convergence 2020
Tocilizumab for COVID-19 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial
John Stone¹, ¹Massachusetts General Hospital, Boston, MA
Background/Purpose: The efficacy of interleukin-6 receptor blockade in hospitalized COVID-19 patients not on mechanical ventilation is unclear.Methods: We performed a randomized, double-blind, placebo-controlled trial in…
Abstract Number: 0017 • ACR Convergence 2020
Impact of COVID19 on Missed/Cancelled Rheumatology Office Visits and Parenteral Immunosuppressive Medications
Daniel Watrous¹, Glenn Parris², Priya Reddy³, Jeffrey Alper⁴, Fenglong Xie⁵, Maria (Maio) Danila⁶, Michael George⁷, William Nowell⁸, Joel Kallich⁹ and Jeffrey R Curtis¹⁰, ¹Sierra Pacific Arthritis, Visalia, CA, ²PARRIS & ASSOCIATES, Lilburn, GA, ³Southwest Florida Rheumatology, Riverview, FL, ⁴Medallion Clinical Research Institute, LLC, Naples, FL, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham (UAB), Birmingham, AL, ⁷University of Pennsylvania, Philadelphia, PA, ⁸Global Healthy Living Foundation, New York City, NY, ⁹Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, ¹⁰Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: The global COVID19 pandemic has had a major impact on healthcare. The effect on rheumatology patients and providers is unclear, as is the role…
Abstract Number: 0442 • ACR Convergence 2020
Disparities in CoronaViridae Infection Are Readily Apparent in Rheumatology Patients Despite Use of Hydroxychloquine And/or Methotrexate
Maria Antonelli¹ and Nora Singer², ¹MHMC/CWRU, Cleveland, OH, ²The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: In the initial months of the SARS CoV2/COVID19 pandemic, broad use of off-label therapy with hydroxychloroquine (HCQ) was prescribed to reduce CoV2-related morbidity and…
Abstract Number: 0597 • ACR Convergence 2020
Telemedicine in Pediatric Rheumatology During COVID-19: The PR-COIN Experience
Y. Ingrid Goh¹, Nancy Pan², Julia Harris³, Andrew Warmin⁴, Janalee Taylor⁴, Sheetal Vora⁵, Fatima Barbar-Smiley⁶, Jon Burnham⁷, Tzielan Lee⁸, Cagri Yildirim-Toruner⁹, Kendra Wiegand¹⁰ and Esi Morgan¹¹, ¹The Hospital for Sick Children, Toronto, ON, Canada, ²Hospital for Special Surgery, New York, NY, ³Children's Mercy Kansas City, Overland Park, KS, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Atrium Health Levine Children's Hospital, Charlotte, NC, ⁶Nationwide Children's Hospital/The Ohio State University, Columbus, OH, ⁷Children's Hospital of Philadelphia, Philadelphia, PA, ⁸Stanford University School of Medicine, Palo Alto, CA, ⁹Nationwide Children's Hospital, Houston, TX, ¹⁰Cincinnati Children's Hospital, Cincinnati, ¹¹Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Healthcare teams were forced to rethink the way they practiced medicine during the COVID-19 pandemic. Many teams transitioned from conducting in-person visits to virtual…
Abstract Number: 0640 • ACR Convergence 2020
Covid-19 and Rheumatic and Musculoskeletal Disease Patients: Infection Rates, Attitudes and Medication Adherence
Kieran Murray¹, Sean Quinn², Matthew Turk², Anna O'Rourke³, Eamonn Molloy¹, Lorraine O'Neill⁴, Anne Mongey⁵, Ursula Fearon⁶ and Douglas Veale⁷, ¹Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ²Saint Vincent's University Hospital, Dublin 4, Ireland, ³Saint James' University Hospital, Dublin 6, Ireland, ⁴Saint Vincent's University Hospital, Dublin, Ireland, ⁵Saint Vincent's University Hospital, Co Dublin, Ireland, ⁶Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Covid-19 has caused >400,000 deaths. The relationship between RMDs, immunosuppressive medications and Covid-19 is unclear. This study explores Covid-19 prevalence, DMARD adherence, information sources…
Abstract Number: 1301 • ACR Convergence 2020
Characterizing How SLE Patients Access Health Information Pre and During COVID-19
Francesca Cardwell¹, Susan Elliott², May Choi³, Ricky Chin⁴ and Ann Clarke⁵, ¹University of Waterloo, Burlington, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Brigham and Women's Hospital | Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵University of Calgary, Calgary, Canada
Background/Purpose: The spread of misinformation related to COVID-19 has been especially acute for SLE patients as unsubstantiated claims regarding the efficacy of antimalarials for COVID-19…
Abstract Number: 1769 • ACR Convergence 2020
Patient-reported COVID-19 Infection in Pregnant Women with Rheumatic Disease: Data from the COVID-19 Global Rheumatology Alliance Patient Experience Survey
Jonathan Hausmann¹, Emily Sirotich², Bonnie Bermas³, Megan Clowse⁴, Milena Gianfrancesco⁵, Pedro M Machado⁶, Helen Robinson⁷, Anja Strangfeld⁸, Jinoos Yazdany⁹ and Philip Robinson¹⁰, ¹Boston Children's Hospital / Beth Israel Deaconess Medical Center, Cambridge, MA, ²McMaster University, Hamilton, ON, Canada, ³UTSouthwestern.edu, Dallas, TX, ⁴Duke University, Chapel Hill, NC, ⁵University of California, San Francisco, San Francisco, CA, ⁶University College London, London, United Kingdom, ⁷University of Queensland School of Medicine, HERSTON, Queensland, Australia, ⁸German Rheumatism Research Center, Berlin, Germany, ⁹UCSF, San Francisco, CA, ¹⁰University of Queensland, Herston, Queensland, Australia
Background/Purpose: The impact of COVID-19 on pregnancy in patients with rheumatic disease is unknown. We describe COVID-19 outcomes in pregnant women with rheumatic disease who…
Abstract Number: 0018 • ACR Convergence 2020
PROMIS-29 and Health Related Quality of Life in Rheumatology Outpatients During the COVID-19 Pandemic in New York City
Gregory Vitone¹, Marianna Frey², Candace Feldman³, Lindsay Lally², Anne Bass⁴, Jane Salmon², Mary Crow², Michael Lockshin⁵, Vivian Bykerk², Medha Barbhaiya⁵ and Lisa Mandl², ¹Hospital for Special Surgery, New York, ²Hospital for Special Surgery, New York, NY, ³Brigham and Women's Hospital, Boston, MA, ⁴Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Barbara Volcker Center for Women and Rheumatic Diseases, New York, NY
Background/Purpose: Little is known about the general health and wellbeing of patients with systemic rheumatic diseases (SRD) during the COVID pandemic. We sought to compare…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].